Physician profile
Meredith Maxwell
NPI 1689845406
$1,030.81
in general payments reported to CMS, 2019-2025
13 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $337 · 2024: $263 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $336.60 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $174.94 | 2024-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $154.12 | 2023-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $98.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $81.90 | 2023-2025 | Ozempic, Rybelsus |
| Shield Therapeutics INC | $50.73 | 2023-2025 | Accrufer |
| Amgen INC. | $36.37 | 2025 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $17.63 | 2025 | Zoryve |
| Pfizer INC. | $17.48 | 2025 | |
| Phadia US INC. | $17.35 | 2023 | Immunocap |
| Idorsia Pharmaceuticals US INC | $15.96 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $14.98 | 2023 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.35 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.